Prognostic Value of Programmed Cell Death Ligand-1 Expression in Ovarian Cancer: an Updated Meta-analysis

Overview

Journal Obstet Gynecol Sci

Specialty Gynecology & Obstetrics

Date 2020 Jun 4

PMID 32489980

Citations 7

Authors

Jinlan Piao

Hyun Ji Lim

Maria Lee

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.

Methods: PubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PD-L1 expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer was assessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation of Gynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg's Funnel plot and Egger's linear test were used to evaluate publication bias. Random-effects model was implemented when significant between-study heterogeneity (I>50%) was observed.

Results: We found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95-1.36; I=78%) or PFS (HR, 1.07; 95% CI, 0.88-1.30; I=75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associated with poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07-1.481; I=59%). We found that upregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76-1.26; I=74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03-1.61; I=64%) Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovarian cancer (HR, 1.12; 95% CI, 0.96-1.29; I=37%).

Conclusion: Our meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer.

Citing Articles

Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors.

Shalaby A, Shalaby O, Abdullah H, Boulassel M, Arafa M Clin Transl Oncol. 2024; 27(2):699-705.

PMID: 39090421 PMC: 11782382. DOI: 10.1007/s12094-024-03613-2.

Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis.

Kang J, Han K, Jung H, Kim H Diagnostics (Basel). 2023; 13(20).

PMID: 37892079 PMC: 10606661. DOI: 10.3390/diagnostics13203258.

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.

Fanale D, Brando C, Corsini L, Cutaia S, Di Donna M, Randazzo U BMC Cancer. 2023; 23(1):437.

PMID: 37179293 PMC: 10183131. DOI: 10.1186/s12885-023-10911-5.

Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.

Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Gojnic Dugalic M Clinics (Sao Paulo). 2023; 78:100204.

PMID: 37148829 PMC: 10757273. DOI: 10.1016/j.clinsp.2023.100204.

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.

Turinetto M, Scotto G, Tuninetti V, Giannone G, Valabrega G Front Oncol. 2021; 11:689829.

PMID: 34195090 PMC: 8238121. DOI: 10.3389/fonc.2021.689829.

References

Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K . IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015; 112(9):1501-9. PMC: 4453666. DOI: 10.1038/bjc.2015.101. View

Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127):127ra37. PMC: 3568523. DOI: 10.1126/scitranslmed.3003689. View

Cha Y, Kim H, Lee C, Cho B, Shim H . Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer. 2016; 97:73-80. DOI: 10.1016/j.lungcan.2016.05.001. View

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K . Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(9):3360-5. PMC: 1805580. DOI: 10.1073/pnas.0611533104. View

Quandt D, Jasinski-Bergner S, Muller U, Schulze B, Seliger B . Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med. 2014; 12:151. PMC: 4079621. DOI: 10.1186/1479-5876-12-151. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

Kleffel S, Posch C, Barthel S, Mueller H, Schlapbach C, Guenova E . Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015; 162(6):1242-56. PMC: 4700833. DOI: 10.1016/j.cell.2015.08.052. View

Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

10.

Kim H, Kim J, Lee Y, Kim S, Lee J, Nam E . Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Gynecol Oncol. 2018; 151(3):414-421. DOI: 10.1016/j.ygyno.2018.08.023. View

11.

Tai H, Yang Q, Wu Z, Sun S, Cao R, Xi Y . PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. J Immunol Res. 2018; 2018:9485285. PMC: 5964418. DOI: 10.1155/2018/9485285. View

12.

Zhu J, Wen H, Bi R, Wu Y, Wu X . Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017; 28(6):e77. PMC: 5641527. DOI: 10.3802/jgo.2017.28.e77. View

13.

Enwere E, Kornaga E, Dean M, Koulis T, Phan T, Kalantarian M . Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017; 30(4):577-586. DOI: 10.1038/modpathol.2016.221. View

14.

Wang Q, Lou W, Di W, Wu X . Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol. 2017; 52:7-14. DOI: 10.1016/j.intimp.2017.08.017. View

15.

Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe K . The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer. 2017; 25(1):34-42. DOI: 10.1007/s12282-017-0781-0. View

16.

Huang L, Deng X, Chang F, Wu X, Wu Y, Diao Q . Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97(43):e12858. PMC: 6221561. DOI: 10.1097/MD.0000000000012858. View

17.

Darb-Esfahani S, Kunze C, Kulbe H, Sehouli J, Wienert S, Lindner J . Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2015; 7(2):1486-99. PMC: 4811475. DOI: 10.18632/oncotarget.6429. View

18.

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

19.

Chatterjee J, Dai W, Abd Aziz N, Teo P, Wahba J, Phelps D . Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer. Clin Cancer Res. 2016; 23(13):3453-3460. DOI: 10.1158/1078-0432.CCR-16-2366. View

20.

Thompson R, Gillett M, Cheville J, Lohse C, Dong H, Webster W . Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004; 101(49):17174-9. PMC: 534606. DOI: 10.1073/pnas.0406351101. View